Trials / Terminated
TerminatedNCT00844727
Coxib-inhibition of Duodenal Polyp Growth in FAP
Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rofecoxib | |
| DRUG | placebo | placebo pills |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2009-02-16
- Last updated
- 2011-07-06
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT00844727. Inclusion in this directory is not an endorsement.